Valuation: Monopar Therapeutics Inc.

Market Cap 637M 559M 514M 479M 904M 60.52B 922M 6.19B 2.4B 29.71B 2.39B 2.34B 103B P/E 2026 *
-41.2x
P/E 2027 * -27.4x
Enterprise Value 518M 455M 419M 390M 736M 49.25B 751M 5.04B 1.95B 24.17B 1.95B 1.9B 84.13B EV / Sales 2026 *
-
EV / Sales 2027 * 33.1x
Free-Float
76.77%
Yield 2026 *
-
Yield 2027 * -
1 day+2.64%
1 week+6.79%
Current month+2.64%
1 month+47.56%
3 months+71.57%
6 months+45.53%
Current year+45.53%
1 week 85.7
Extreme 85.7
100.32
1 month 57.7
Extreme 57.7
100.32
Current year 50.07
Extreme 50.07
100.32
1 year 29.18
Extreme 29.18
105
3 years 1.37
Extreme 1.3695
105
5 years 1.37
Extreme 1.3695
105
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 01/12/2014
Director of Finance/CFO 54 03/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 01/12/2014
Chairman 73 01/12/2014
Director/Board Member 84 01/04/2017
Date Insider Type Main position Quantity % Market Cap.
06-26Free

Director

1,284 0.0192%
03-31Fiscal year

Founder

15,436 0.2310%
03-31Fiscal year

Chief Operating Officer

8,599 0.1287%
Change 5-day change 1-year change 3-year change Capi.($)
+2.64%+6.79%+183.16%+2,122.92% 637M
+0.89%+5.44%+1.36%+6.99% 48.62B
+0.12%+10.45%+408.29%+600.97% 39.86B
+5.17%+9.47%+24.96%-9.60% 33.91B
+2.02%+4.91%+18.59%+63.06% 32.32B
+0.69%+1.04%+14.23%+30.86% 24.73B
+0.40%+12.51% - - 16.63B
+2.64%+6.00%+69.30%+126.33% 15.52B
+0.91%+1.08%+13.78%+18.51% 13.63B
+0.77%+10.67%+17.58%-30.04% 13.41B
Average +1.61%+7.02%+83.47%+325.56% 23.93B
Weighted average by Cap. +1.57%+7.14%+88.74%+134.45%

Financials

2026 *2027 *
Net sales - 15.85M 13.92M 12.81M 11.94M 22.51M 1.51B 22.97M 154M 59.69M 740M 59.51M 58.22M 2.57B
Net income -20.16M -17.7M -16.29M -15.18M -28.63M -1.92B -29.22M -196M -75.93M -941M -75.7M -74.06M -3.27B -35.78M -31.41M -28.91M -26.94M -50.81M -3.4B -51.84M -348M -135M -1.67B -134M -131M -5.81B
Net Debt -119M -104M -95.82M -89.29M -168M -11.27B -172M -1.15B -447M -5.53B -445M -436M -19.26B -112M -98.63M -90.79M -84.6M -160M -10.68B -163M -1.09B -423M -5.24B -422M -413M -18.25B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
22
Date Price Change Volume
01/07/26 $95.03 +2.64% 177,531
30/06/26 $92.59 -2.08% 111,800
29/06/26 $94.56 +7.85% 119,921
26/06/26 $87.68 +0.06% 310,268
25/06/26 $87.63 -1.53% 203,061
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
95.03USD
Average target price
113.62USD
Spread / Average Target
+19.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock